drugset / Trial / NCT04239014
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
RandomizedParallel-groupDouble-blindTreatment
Summary
To investigate the effectiveness and tolerability of a second maintenance treatment in participants with platinum-sensitivity relapsed (PSR) epithelial ovarian cancer, who have previously received PARPi maintenance treatment and who have benefit (complete response \[CR\] or partial response \[PR\]) or stable disease (SD) from further platinum based chemotherapy.
Timeline
- Start
- 2020-08-07
- Primary completion
- 2021-01-25
- Completion
- 2021-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceralasertib | Small molecule | 160 mg | Oral |
| Subject | Olaparib | Small molecule | 300 mg | Oral |